home / stock / mdnaf / mdnaf quote
Last: | $1.51 |
---|---|
Change Percent: | -1.24% |
Open: | $1.63 |
Close: | $1.51 |
High: | $1.64 |
Low: | $1.495 |
Volume: | 61,328 |
Last Trade Date Time: | 07/29/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.51 | $1.63 | $1.51 | $1.64 | $1.495 | 61,328 | 07-29-2024 |
$1.61 | $1.5696 | $1.61 | $1.627 | $1.55 | 133,481 | 07-26-2024 |
$1.53 | $1.4 | $1.53 | $1.6273 | $1.36 | 188,179 | 07-25-2024 |
$1.4 | $1.41 | $1.4 | $1.4328 | $1.39 | 43,026 | 07-24-2024 |
$1.42 | $1.4215 | $1.42 | $1.44 | $1.4 | 39,904 | 07-23-2024 |
$1.43 | $1.35 | $1.43 | $1.43 | $1.35 | 21,489 | 07-22-2024 |
$1.41 | $1.4092 | $1.41 | $1.42 | $1.36 | 47,335 | 07-19-2024 |
$1.395 | $1.46 | $1.395 | $1.5 | $1.35 | 84,957 | 07-18-2024 |
$1.47 | $1.55 | $1.47 | $1.55 | $1.45 | 61,260 | 07-17-2024 |
$1.55 | $1.54 | $1.55 | $1.5775 | $1.47 | 122,475 | 07-16-2024 |
$1.51 | $1.55 | $1.51 | $1.68 | $1.48 | 76,388 | 07-15-2024 |
$1.5531 | $1.41 | $1.5531 | $1.6612 | $1.4 | 154,820 | 07-12-2024 |
$1.4 | $1.345 | $1.4 | $1.468 | $1.345 | 135,088 | 07-11-2024 |
$1.36 | $1.35 | $1.36 | $1.432 | $1.35 | 21,437 | 07-10-2024 |
$1.4 | $1.434 | $1.4 | $1.4352 | $1.36 | 31,785 | 07-09-2024 |
$1.43 | $1.3814 | $1.43 | $1.44 | $1.3814 | 20,604 | 07-08-2024 |
$1.39 | $1.37 | $1.39 | $1.4 | $1.35 | 31,879 | 07-05-2024 |
$1.3725 | $1.386 | $1.3725 | $1.386 | $1.33 | 19,337 | 07-04-2024 |
$1.3725 | $1.386 | $1.3725 | $1.386 | $1.33 | 19,337 | 07-03-2024 |
$1.41 | $1.45 | $1.41 | $1.45 | $1.36 | 67,286 | 07-02-2024 |
News, Short Squeeze, Breakout and More Instantly...
Increased cash balance to $37 million following a $20 million investment by RA Capital extending runway into mid-2026 MDNA11 continues to exhibit compelling deep and durable single agent activity and best-in-class potential relative to other IL-2 therapies in clinical development ...
- ABILITY-1 study is currently enrolling patients for the treatment of advanced solid tumors with MDNA11, a novel long-acting IL-2 super-agonist, as a monotherapy or in combination with KEYTRUDA ® , at clinical trial sites in U.S.A., Canada, Australia, and Korea - Monot...
Single treatment with bizaxofusp achieved significant survival benefit (mOS of 13.5 vs. 7.2 months, p=0.009) and reduced risk of death by almost half ( hazard ratio: 0.54, 95% confidence interval: 0.34-0.83) versus a propensity balanced external control (EC) arm irrespective of IL...